Last updated: August 19, 2026
ecutive summary: Fluorescein sodium and benoxinate hydrochloride ophthalmic solution is a mature diagnostic product, typically supplied at 0.25% fluorescein sodium and 0.4% benoxinate hydrochloride. Its active-ingredient and basic formulation patent exposure is likely weak because both actives and the combination have long clinical histories. Commercial value is concentrated in preservative-free unit-dose delivery, low-irritation excipient systems, sterile packaging, supply reliability, and institutional workflow economics. The strongest opportunity is a differentiated ophthalmic presentation rather than a new chemical entity or conventional composition patent.
Fluorescein Sodium and Benoxinate Hydrochloride Excipient Strategy and Commercial Opportunities
What is fluorescein sodium and benoxinate hydrochloride ophthalmic solution?
The product combines a diagnostic dye with a topical ophthalmic anesthetic:
| Component |
Typical concentration |
Function |
| Fluorescein sodium |
0.25% |
Stains corneal epithelial defects and supports ophthalmic examination |
| Benoxinate hydrochloride |
0.4% |
Produces topical ocular anesthesia |
| Boric acid |
Varies by product |
Buffering and tonicity contribution |
| Edetate disodium |
Varies by product |
Chelation and stability support |
| Sodium chloride |
Varies by product |
Tonicity adjustment |
| Water for injection |
q.s. |
Sterile vehicle |
The combination is used before procedures such as tonometry, gonioscopy, foreign-body removal, and contact-lens-related examination. FDA labeling identifies the product as a sterile ophthalmic solution and warns against prolonged or unsupervised use because topical ocular anesthetics can delay healing and cause corneal injury with misuse (U.S. Food and Drug Administration [FDA], 2024a).
Commercial products have historically been sold under branded and generic labels, including Fluress and products described as fluorescein sodium and benoxinate hydrochloride ophthalmic solution USP.
What excipients are used in the reference formulation?
Public labeling identifies a relatively simple aqueous excipient system. The principal formulation functions are pH control, tonicity adjustment, metal-ion control, and sterile preservation or preservative-free packaging.
Formulation functions
| Excipient function |
Common formulation approach |
Commercial rationale |
| Vehicle |
Water for injection |
Standard sterile ophthalmic base |
| Buffer |
Boric acid or borate system |
Controls pH and contributes to tonicity |
| Tonicity |
Sodium chloride, boric acid, or combined system |
Reduces ocular discomfort |
| Chelation |
Edetate disodium |
Limits metal-catalyzed degradation and supports preservative performance |
| Preservation |
Product-specific preservative or preservative-free container |
Determines packaging, labeling, and clinical positioning |
| pH adjustment |
Hydrochloric acid or sodium hydroxide, if required |
Controls comfort, solubility, and stability |
The exact qualitative and quantitative composition must be taken from the target product’s current approved labeling and chemistry, manufacturing, and controls file. Substituting a buffer, preservative, surfactant, or container can create a different regulatory product even where the active concentrations remain unchanged.
Which excipient strategy offers the strongest commercial opportunity?
The best opportunity is a preservative-free, single-use presentation for high-frequency clinical settings. The product is applied directly to the eye and may be used repeatedly across a procedure day. That creates a commercial case for limiting preservative exposure and reducing contamination risk.
1. Preservative-free unit-dose ampoules
A unit-dose product can target:
- Ophthalmology clinics
- Optometry practices
- Ambulatory surgery centers
- Emergency departments
- Hospital formularies
- Mobile eye-care programs
- Pediatric and contact-lens examination settings
Potential benefits include lower preservative exposure, reduced multidose contamination risk, and simpler inventory control. The principal disadvantages are higher packaging cost, more material usage, and possible difficulty dispensing enough solution for bilateral procedures.
The product should be designed around a container that supports:
- Low residual volume
- One-handed opening
- Controlled drop formation
- Low extractables and leachables
- Compatibility with the dye
- Adequate label space for lot and expiry data
- Robust transport performance
A low-cost polyethylene or polypropylene blow-fill-seal system could be commercially attractive, but the container-closure system would require extractables, leachables, sterility, particulate, and container-integrity evaluation under applicable ophthalmic standards.
2. Preservative-reduced or low-irritation multidose packaging
A multidose presentation can preserve lower manufacturing and distribution costs. The commercial challenge is differentiation. A conventional bottle containing the same active concentrations will have limited pricing power unless it offers a meaningful packaging or safety advantage.
Potential options include:
- Metered-dose multidose dispensers
- One-way valve bottles
- Preservative-free multidose systems
- Low-volume containers with reduced waste
- Tamper-evident hospital packaging
A preservative-free multidose system is more difficult than a unit-dose format because microbial protection must come from the container and dispensing architecture rather than from the formulation. The device becomes a central part of the regulatory strategy.
3. Optimized buffer and tonicity system
Boric acid and sodium chloride are familiar ophthalmic excipients, but the balance affects comfort, osmolality, pH, dye stability, and compatibility with benoxinate hydrochloride.
A development program should compare:
- Borate-buffered systems
- Phosphate-buffered systems
- Citrate-buffered systems
- Low-buffer-capacity systems
- Sodium chloride-only tonicity adjustment
- Combined borate and sodium chloride systems
A low-buffer-capacity system may reduce formulation complexity but can provide less resistance to pH drift. Phosphate systems may require closer assessment of precipitation, container interaction, and ocular tolerability. Citrate systems can provide useful buffering but may affect sensory characteristics and compatibility with other components.
The commercial objective should not be a novel excipient claim by itself. It should be a formulation with measurable benefits such as lower sting, lower variability in pH, longer in-use stability, or improved compatibility with preservative-free packaging.
What formulation patents could protect a new product?
Formulation patent value would depend on a specific, non-obvious technical result. Broad claims covering fluorescein sodium, benoxinate hydrochloride, water, boric acid, sodium chloride, or EDTA would face substantial prior-art risk.
Potentially protectable subject matter includes:
| Potential claim area |
Strength potential |
| Novel preservative-free multidose container |
Moderate if device performance is distinctive |
| Specific excipient ratios linked to stability or tolerability |
Moderate, subject to comparative data |
| Reduced-irritation formulation with defined pH and osmolality |
Moderate to weak without unexpected results |
| Long-term stability of fluorescein and benoxinate combination |
Moderate if supported by robust data |
| Low-extractables container-closure system |
Moderate, usually stronger as device or combination claims |
| Single-use packaging with controlled dose delivery |
Moderate |
| Manufacturing process that reduces degradation or particulates |
Moderate |
| Broad use of known ophthalmic excipients |
Weak |
A credible patent position would require comparative evidence against the marketed formulation and relevant prior art. Useful data would include assay, degradation products, pH, osmolality, appearance, particulate matter, sterility, container integrity, preservative effectiveness where applicable, and ocular irritation testing.
What is the patent and exclusivity position?
The combination is a legacy ophthalmic product. Fluorescein sodium and benoxinate hydrochloride are established active ingredients, and the active concentrations have been used in marketed ophthalmic products for many years. The commercial estate is therefore unlikely to depend on a recently issued composition-of-matter patent.
Orange Book status
FDA Orange Book treatment depends on the specific reference-listed drug, approved application, and current patent or exclusivity entries. A product-specific review should distinguish:
- The reference-listed drug
- Approved ANDAs
- Current patent listings
- Paragraph IV certifications
- Delisted or discontinued products
- Whether an application is eligible for approval based on an active listed drug
The existence of an approved generic does not eliminate the need to confirm the current reference product and FDA-approved formulation. Orange Book records can change as products are withdrawn, transferred, or updated (FDA, 2024b).
Patent expiration dates
No commercially meaningful active-ingredient patent term is expected to drive this product category. Any relevant patent expiry would more likely involve:
- A specific container system
- A preservative-free multidose device
- A formulation with defined stability characteristics
- A manufacturing process
- A method of reducing ocular irritation
Those rights would not necessarily appear as broad Orange Book patents unless they are submitted and accepted for listing under FDA rules.
Paragraph IV risk
A conventional generic applicant could pursue an ANDA if a suitable reference-listed drug and pathway are available. A Paragraph IV challenge would be relevant only if the reference product has an unexpired Orange Book-listed patent. For a legacy combination with no apparent active composition patent, the principal approval issues are likely to be pharmaceutical equivalence, bioequivalence or comparative performance requirements, sterility, container-closure suitability, and labeling.
A differentiated preservative-free or device-based product may not fit a simple generic strategy. It could require a 505(b)(2) application if it relies on an approved product but introduces a new formulation, delivery system, dosing presentation, or other change requiring FDA reliance on prior findings plus new investigations (FDA, 2024c).
What regulatory pathway is most suitable?
ANDA pathway
An ANDA is most suitable when the proposed product matches the reference product in active ingredients, strength, dosage form, route, and relevant product characteristics. The applicant must establish pharmaceutical equivalence and demonstrate that the formulation and container do not create clinically meaningful differences.
The ANDA strategy favors:
- Conventional aqueous solution
- Same active concentrations
- Similar excipient profile
- Same ophthalmic route
- Standard multidose or unit-dose packaging
- No new clinical use claims
505(b)(2) pathway
A 505(b)(2) application may be more suitable for:
- Preservative-free multidose delivery
- A new container-closure system
- A materially different excipient system
- New dosing instructions
- Reduced-waste presentation
- A formulation supported by new local tolerability data
The 505(b)(2) route offers greater product differentiation but can generate additional clinical, chemistry, device, and patent-related obligations. The applicant must assess whether the proposed changes require new clinical or nonclinical evidence.
How does fluorescein sodium and benoxinate compare with competing products?
The closest competitors are not necessarily chemically identical. They include standalone fluorescein products, standalone ophthalmic anesthetics, fluorescein strips, and alternative diagnostic dyes.
| Product category |
Advantages |
Disadvantages |
| Fluorescein/benoxinate solution |
Combined staining and anesthesia; efficient procedure workflow |
Sterile liquid handling; preservative concerns |
| Fluorescein sodium solution |
Diagnostic function without anesthetic |
Requires separate anesthetic when needed |
| Fluorescein strips |
Low liquid volume; convenient storage |
Additional handling; variable wetting and dose delivery |
| Benoxinate solution alone |
Flexible anesthetic use |
Requires separate fluorescein product |
| Fluorescein with another anesthetic |
Potential formulation or supply alternative |
May face limited clinical familiarity |
| Preservative-free unit dose |
Lower contamination and preservative concerns |
Higher packaging and logistics cost |
The combination product has workflow value because it reduces the number of administered products during an examination. That advantage can support formulary adoption even when the active ingredients are not differentiated.
Which companies are positioned to compete?
Competition is likely to come from:
- Legacy ophthalmic generic manufacturers
- Sterile ophthalmic contract manufacturers
- Specialty ophthalmology companies
- Device manufacturers with unit-dose or preservative-free delivery systems
- Suppliers of fluorescein strips and standalone anesthetic products
The strongest competitive assets are sterile manufacturing capacity, reliable supply of pharmaceutical-grade active ingredients, validated ophthalmic filling, and access to ophthalmology distribution channels. A company without sterile ophthalmic infrastructure may need a contract development and manufacturing organization, increasing cost and reducing control over capacity.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers
The main technical barriers are:
- Sterile solution manufacture
- Aseptic filling or validated terminal sterilization where appropriate
- Control of visible and subvisible particles
- Dye-related staining of equipment and packaging
- Container-closure integrity
- Accurate low-volume filling
- Stability of both active ingredients
- Control of degradation products
- Compatibility with elastomers, plastics, and labels
Fluorescein can create visual challenges during inspection and may interact with packaging materials or manufacturing surfaces. The finished product must remain within specifications for assay, impurities, pH, osmolality, sterility, and appearance throughout shelf life.
Intellectual-property barriers
The likely IP barriers are narrower than the manufacturing barriers. A new entrant should focus freedom-to-operate review on:
- Preservative-free ophthalmic containers
- Metered-dose dispensing systems
- Blow-fill-seal technologies
- Specific excipient combinations
- Use of chelators in ophthalmic solutions
- Packaging claims related to contamination control
- Patents held by device suppliers
A broad patent on the active combination is less likely to be the principal obstacle than a device patent or a manufacturing license requirement.
What revenue exposure and commercial upside are available?
Public product-level revenue data for this combination are not generally disclosed. The product is more likely to be a modest ophthalmic specialty opportunity than a large branded-pharmaceutical franchise.
Revenue potential depends on:
- Procedure volume in ophthalmology and optometry.
- Whether the product is sold through hospital contracts or retail channels.
- Unit-dose versus multidose manufacturing cost.
- Generic price competition.
- Supply reliability and back-order performance.
- Ability to secure formulary conversion.
- Differentiation through preservative-free packaging.
- Geographic registration and distribution.
A conventional generic may achieve volume but limited margin. A preservative-free unit-dose product can support higher pricing if it demonstrates lower waste, better contamination control, or improved tolerability. A device-enabled product has greater upside but also greater development and regulatory cost.
What generic launch scenarios exist?
Scenario 1: Conventional generic solution
This is the lowest-cost strategy. It offers the fastest route to market if a suitable reference product is available, but it is exposed to price erosion and limited differentiation.
Scenario 2: Preservative-free unit-dose product
This strategy targets institutional and high-volume clinical users. It can command a premium but requires packaging validation, higher production cost, and careful supply planning.
Scenario 3: Preservative-free multidose system
This has the strongest differentiation potential. The product would compete on convenience and contamination control, but device performance becomes a central approval and liability issue.
Scenario 4: Fluorescein-only or benoxinate-only line extension
A company could build a broader ophthalmic diagnostic portfolio by selling the combination alongside standalone fluorescein and anesthetic products. This may improve account penetration but would not create strong exclusivity by itself.
Key Takeaways
- The combination is a mature ophthalmic diagnostic and anesthetic product with limited apparent active-ingredient patent strength.
- Excipients should be selected around comfort, stability, tonicity, preservative strategy, and container compatibility.
- Preservative-free unit-dose delivery is the clearest commercial opportunity.
- Preservative-free multidose packaging offers more differentiation but creates greater device and regulatory complexity.
- Broad formulation patents are likely weak unless supported by unexpected stability, tolerability, or packaging results.
- An ANDA is appropriate for a conventional equivalent solution; a 505(b)(2) strategy may be better for a materially differentiated formulation or delivery system.
- Manufacturing capability, sterile supply reliability, and packaging IP are likely to matter more than active-ingredient exclusivity.
- Product-level revenue is not publicly established, so the opportunity should be evaluated through procedure volume, formulary access, unit economics, and pricing durability.
FAQs
Does fluorescein sodium and benoxinate hydrochloride require a preservative?
Not necessarily. The product can be developed in a preservative-containing multidose format or a preservative-free unit-dose format. The choice affects packaging, sterility controls, in-use stability, labeling, and commercial positioning.
Can benzalkonium chloride be used in this ophthalmic combination?
It may be technically feasible in some multidose formulations, but its concentration and use require evaluation of ocular tolerability, preservative effectiveness, labeling, and compatibility with the target patient population. A preservative-free alternative may offer stronger commercial differentiation.
Is fluorescein sodium and benoxinate hydrochloride a biologic or biosimilar product?
No. It is a small-molecule ophthalmic drug product. Biosimilar regulation does not apply. Generic drug and, for certain differentiated products, 505(b)(2) pathways are the relevant FDA frameworks.
Can a new excipient create market exclusivity for this product?
An excipient alone rarely creates meaningful exclusivity. A patent position is more credible when the excipient system is tied to a defined technical result, such as improved stability, reduced irritation, preservative-free multidose performance, or reduced extractables.
What geographic markets are most attractive?
The United States offers a defined FDA pathway and an established ophthalmic procedure market. Europe, Canada, Japan, and selected emerging markets may offer opportunities for unit-dose and preservative-free products, but registration requirements, reference-product availability, sterile manufacturing standards, and reimbursement economics differ by jurisdiction.
References
-
U.S. Food and Drug Administration. (2024a). Fluorescein sodium and benoxinate hydrochloride ophthalmic solution prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
U.S. Food and Drug Administration. (2024c). Applications covered by section 505(b)(2). FDA Guidance and Regulatory Information.
-
United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.
-
U.S. Food and Drug Administration. (2024d). Container closure systems for packaging human drugs and biologics. FDA guidance.
